Too many patients and families continue to experience the effects of serious health conditions that have no available treatments or cures.
AMAG seeks to collaborate on and acquire promising therapies at various stages of development, and advance them through the clinical and regulatory process to deliver new treatment options to patients.
As part of our commitment to advance the body of clinical research in maternal health, we have made a significant investment in the late-stage development program of an investigational therapy—digoxin immune fab (DIF)—for the treatment of severe preeclampsia. This potentially life-threatening condition is a contributing factor in a significant number of preterm births in the U.S., yet no approved treatment options currently exist.1
To further complement and leverage our existing hematology portfolio, we have acquired ciraparantag, an anticoagulant reversal agent. Ciraparantag is being developed for patients treated with novel oral anticoagulants or low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled bleeding. Ciraparantag has been granted Fast Track review designation by the U.S. Food and Drug Administration (FDA) and has patent protection until 2034.